Conference Coverage

PSYCHIATRY UPDATE 2017


 

Beyond Efficacy and Effectiveness: Neurotoxicity vs Neuroprotection are the REAL Differences Between Typical and Atypical Antipsychotics


Henry A. Nasrallah, MD, Saint Louis University School of Medicine

Dr. Nasrallah discussed the difference between typical vs atypical antipsychotics—the former is neurotoxic, the latter is neuroprotective. Because patients with schizophrenia experience a loss of brain volume and cerebral grey matter and increased lateral ventricle volume, consider atypical antipsychotics for their neuroprotective properties.

In several studies typical antipsychotics, such as haloperidol, have been found to be neurotoxic, causing apoptosis and decreased cell viability. Atypical antipsychotics may be beneficial for patients with schizophrenia because they:

  • stimulate production of new brain cells and increase neurotropic factors
  • reverse PCP-induced changes in gene expression and loss of dendritic spines in the frontal cortex
  • are neuroprotective against ischemic stroke damage
  • prevent oligodendrocyte damage caused by interferon gamma-stimulated microglia.

Pages

Recommended Reading

Risk considerations for suicidal physicians
MDedge Psychiatry
Ask patients about sexual function at first visit
MDedge Psychiatry
Depression and deep brain stimulation: ‘Furor therapeuticus redux’
MDedge Psychiatry
APA task force urges caution in off-label use of ketamine for mood disorders
MDedge Psychiatry
Managing family differences
MDedge Psychiatry
Are new medications on horizon for patients with depression, inflammation?
MDedge Psychiatry
Spousal suicide linked to higher risk of mental, physical disorders
MDedge Psychiatry
Anxiety in children during a new administration; Why medical psychiatry is vital for my patients; And more
MDedge Psychiatry
SPECT reveals perfusion problems in antiphospholipid syndrome
MDedge Psychiatry
In type 2 diabetes, chronotype may affect depressive symptoms
MDedge Psychiatry